Multimodality treatment of pancreatic cancer with liver metastases using chemotherapy, radiation therapy, and/or Chinese herbal medicine.
Multimodality treatment of pancreatic cancer with liver metastases using chemotherapy, radiation therapy, and/or Chinese herbal medicine.
复制标题
DOI：
10.1097/mpa.0b013e3181e6e398
复制
发表时间：
2011-01
期刊：
影响因子：
2.9
通讯作者：
Liu L
中科院分区：
文献类型：
--
作者：
Ouyang H;Wang P;Meng Z;Chen Z;Yu E;Jin H;Chang DZ;Liao Z;Cohen L;Liu L
目的探讨多学科联合治疗胰腺癌合并肝转移的疗效。从2002年到2007年，164例连续接受化疗、放疗和/或中药治疗的PCLM患者被纳入本研究。分析两组患者的临床参数、所接受的治疗及自初诊以来的生存时间。164例患者中，113例（69%）为男性，51例（31%）为女性，中位年龄为58岁。同步肝转移132例（80%），肝外转移57例（35%）。164例患者的总中位生存时间为4.7个月，其中23例（14%）在最初诊断为肝转移后至少存活了12个月。Karnofsky性能状态(KPS) <80、体重下降（6个月内体重下降10%）、腹水和碳水化合物抗原（CA） 19-9≥1000 U/mL是不良生存的最相关预测因素。多因素分析显示化疗和CHM是保护因素。多模式治疗在PCLM患者中耐受性良好，可能有效延长其生存期。了解这些预后因素的影响可能有助于评估患者的生存潜力和选择最合适的治疗方法。
To explore the utility of multidisciplinary approaches in the treatment of patients with pancreatic cancer with liver metastases (PCLM). From 2002 to 2007, a total of 164 consecutive patients with PCLM treated with chemotherapy, radiation therapy, and/or Chinese herbal medicine (CHM) were included in this study. Clinical parameters, treatments received and survival time from initial diagnosis were analyzed. Of the 164 patients, 113 (69%) were men and 51 (31%) were women, with median age of 58 years. One hundred and thirty-two patients (80%) had synchronous liver metastases, and 57 patients (35%) had extrahepatic metastases. Overall median survival time of the 164 patients was 4.7 months, 23 (14%) were alive at least 12 months after initial diagnosis of liver metastases. Karnofsky performance status (KPS) <80, weight loss (>10% within 6 months), ascites, and carbohydrate antigen (CA) 19-9 ≥1000 U/mL were the most relevant predictors of poor survival. Multivariate analysis showed that chemotherapy and CHM were protective factors. Multimodality treatment is well tolerated by patients with PCLM and may be effective in prolonging their survival. Awareness of the implications of these prognostic factors may assist in evaluating the survival potential of patients and selecting the most appropriate treatments.